OfOnline editorial team
The pharmaceutical company AstraZeneca has announced that it will also withdraw the marketing authorizations for Vaxzevria in Europe. The withdrawal due to lack of demand and the surplus of vaccines currently available on the market
AstraZeneca announced Wednesday that it has started the worldwide withdrawal of its vaccine against Covid-19. The pharmaceutical company also added that it will proceed with the withdrawal of the marketing authorizations for the Vaxzevria in Europe.
AstraZeneca gave reasons withdrawal with the lack of demand and surplus of vaccines currently available on the market: «Since numerous updated vaccines have been developed for Covid-19 variants, there is now a excess serum available. This has caused a decrease in demand for Vaxzervria, which is no longer produced or supplied.”
The decision follows the company’s official statement in March on the stop the marketing of the vaccine in the European Union. Tuesday theEuropean agency for medicines has issued a warning that the vaccine is no longer authorized for use.
The vaccine was the subject of a lawsuit filed in London by relatives of British citizens who died from blood clots that appear linked to the AstraZeneca product: «It can cause a very rare side effect, with potentially fatal complications»the lawyers explained in the courtroom at the end of April.
The rare but serious side effect is known as thrombosis with thrombocytopenia or TTS. The rare syndrome occurred in approx two or three people out of 100 thousand vaccinated with Vaxzevria.
May 8, 2024 (modified May 8, 2024 | 09:40)
© ALL RIGHTS RESERVED
